Publication | Closed Access

A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients

Lymphoid NeoplasiaPhase IiMedicineImmunologyAdjuvant Tumour-infiltrating LymphocytesImmunotherapyOncologyRadiation OncologyAdult T-cell Leukemia-lymphomaCancer ResearchCancer-associated Virus